The new ‘next generation’ booster vaccine is an updated version of the Moderna vaccine and has been approved for use in the UK
” src=”https://www.nationalworld.com/jpim-static/image/2022/08/15/12/2.68328149.jpg?width=640&quality=65&smart&enable=upscale” data- hero=”” fetchpriority=”high”/> A ‘next-generation’ Covid-19 booster vaccine, the first to target two strains of the virus, has been approved for use in adults in the UK.
A ‘next-generation’ Covid-19 booster vaccine, the first to target two strains of the virus, has been approved for use in adults in the UK.
The UK has become the first nation to approve a ‘next-generation’ Covid-19 booster shot, the first to target two strains of the virus.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Moderna’s bivalent vaccine, which targets both the original Covid strain and the Omicron variant.
The dose known as mRNA-1273.214 is an updated version of the Moderna vaccine already in use for the first, second and booster doses.
Who gets the vaccine?
It has now been approved for adult use in the UK.
Moderna’s Chief Medical Officer, Dr. Paul Burton previously said the new vaccine can boost a person’s antibodies to levels so high that it may only be needed annually.
Moderna Chief Executive Officer Stephane Bancel described it as a “next-generation Covid-19 vaccine” which will play a “key role in protecting people in the UK from Covid-19” over the winter.
Mr Bancel said: “We are delighted with the MHRA’s approval of Spikevax Bivalent Original/Omicron, our next-generation Covid-19 vaccine.
“This represents the first approval of an Omicron-containing bivalent vaccine, further demonstrating the commitment and leadership of the UK public health authorities in bringing the Covid-19 pandemic to a close.
“This bivalent vaccine plays an important role in protecting people in the UK from Covid-19 as we enter the winter months.”
The MHRA said the vaccine’s side effects are the same as the original Moderna booster dose and were typically mild.
The Chairman of the Board, Dr. June Raine, described the new booster as “a sharpened tool in our armory” to help protect the UK from Covid-19.
This article is continuously updated